Eisai presented new real‑world findings from an analysis of long‑term treatment persistence among early Alzheimer’s disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from the PurpleLab claims database, the analysis showed that most patients continued lecanemab therapy after the initial 18 months of treatment, describes BioArctic in a press release.

In real‑world clinical practice, patients with chronic diseases who stay on their treatments longer tend to experience better clinical outcomes. The results are similar to what was seen in the Phase 3 Clarity AD study where 94% of patients who completed 18 months of lecanemab treatment chose to continue maintenance treatment by enrolling in the subsequent open-label, long-term extension (OLE) study. In the OLE study, patients who stayed on treatment continued to benefit from four years of lecanemab treatment compared with the natural course of Alzheimer’s disease.